[1]Wang H, Liao L, Xu Y, Long Y, Wang Y, Zhou Y. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China. Front Oncol. 2022;12:1081750.

[2]Wang H, Liao L, Xu Y, Long Y, Wang Y, Zhou Y. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China. Front Oncol. 2022;12:1081750.

[3]HaoWang,YeWang,RuixueGong,YuyuGeng,LiLi.Cost effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China[J].Ann Palliat Med. 2021 Nov;10(11):11382-11393.]